* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download 药效学2
Discovery and development of beta-blockers wikipedia , lookup
CCR5 receptor antagonist wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Pharmacognosy wikipedia , lookup
Prescription costs wikipedia , lookup
Drug discovery wikipedia , lookup
Discovery and development of antiandrogens wikipedia , lookup
Pharmacokinetics wikipedia , lookup
5-HT3 antagonist wikipedia , lookup
Drug interaction wikipedia , lookup
Drug design wikipedia , lookup
NMDA receptor wikipedia , lookup
Toxicodynamics wikipedia , lookup
5-HT2C receptor agonist wikipedia , lookup
Discovery and development of angiotensin receptor blockers wikipedia , lookup
Nicotinic agonist wikipedia , lookup
Cannabinoid receptor antagonist wikipedia , lookup
NK1 receptor antagonist wikipedia , lookup
Psychopharmacology wikipedia , lookup
3- Mechanisms of Drug Actions 3.1 Structure-Activity Relationship (构效关系) Both the affinity of a drug and its functional activity are determined by its chemical structure. Relatively minor modifications in the drug molecule may result in major changes in pharmacological properties. CH 2 CH CH 3 O Atropine NCH3 CH CH 2 CH CH CH HO CH CH CH CH CH C6H5 Peripheral & Central CH 2 OH CH 3 O C O CH CH 3 CH 3 C6H5 Scopolamine Central CH 2 OH CH 3 NCH3 CH CH 2 CH CH 3 NCH3 CH O C O O O C CH CH 2 OH Anisodamine C6H5 Peripheral HO HO CH Norepinephrine NH2 CH 2 receptor OH HO HO CH , CH3 OH HO HO Epinephrine NH CH2 receptors CH 3 CH CH 2 N CH CH 3 OH Isoprenaline receptor 3- Mechanisms of Drug Actions 3.2 Non-specific mechanisms (非特异性机制) (1)Physioc-chemical reactions Antacids, mannitol, dextran, …… (2)Membrane-stablizing General anesthetics, ethanol, …… (3)Disinfectants 3- Mechanisms of Drug Actions 3.3 Specific mechanisms (特异性机制) (1) Receptor (受体) (2) Enzyme (酶) (3) Ion channel (离子通道) (4) Transporter (转运体) (5) Immune system (免疫系统) (6) Gene therapy (基因治疗) & genetic engineering drugs (基因工程药物) (7) Others (其他) Specific mechanisms:Actions on cell functions Enzyme-targeting drugs Acetylcholinesterase inhibitor Cyclo-oxygenase inhibitor Angiotensin converting enzyme inhibitor Na+-K+-ATPase inhinitor H+-K+-ATPase inhinitor HMG-CoA reductase inhibitors Most of antibiotics and antitumor drugs Drugs acting on ion channels Neurotransmitter transporter inhibitors Furosemide inhibits Na+-K+-2Cl-transporter Targets of drug 4- Drug receptors Key events in the discovery and establishment of the concept of receptors 4- Drug receptors 4.1 Concept of receptors Receptor: the component of a cell or organism that interacts with a drug and initiates the chain of biochemical events leading to the drug’s observed effects. (受体:细胞膜或细胞质的特异性蛋白质,具有识别、结合配体,并 发生信号转导的作用) Function: recognizing and binding with a specific ligand; signal transduction Structure: a protein with ligand-bingding domain and effector (transducer) domain 4- Drug receptors Ligand: Chemicals that can bind to receptors, including endogenous or exogenous agonists and antagonists (配体:能与受体特异性结合的物质,分为激动剂和拮抗剂; 根据来源分为内源性和外源性两类) 4- Drug receptors Characteristics of receptor (interaction between drug and receptor) a) Sensitivity (灵敏性) b) Specificity (特异性) c) Saturability (饱和性) d) Reversibility (可逆性) e) Multiple-variation (多样性) 4- Drug receptors 4.2 Receptor classification (1) G protein-coupled receptors (G蛋白偶联受体, GPCR, 7TM受体) (2) Ligand-gated ion channel receptors (含离子通道的 受体,配体门控离子通道受体) (3) Receptors as enzymes or coupled by enzymes (具有酪氨酸激酶活性[或偶联]受体, 1TM受体) (4) Cytosolic [or nuclear] receptors (细胞内受体, 核内受体) Another classification (1) Cytosolic [or nuclear] receptors (2) Receptors as enzymes (3) Receptors coupled by enzymes (4) Ligand-gated ion channel receptors (5) G protein-coupled receptors Examples: M cholinoceptor Adrenoceptors 5-HT receptors DA receptors Opioid receptors ect. G protein-coupled receptors (GPCR) GPCR signal transduction PKA IP3-Ca2+ / PKC cAMP-PKA Examples: N cholinoceptor GABAA receptor 5-HT3 receptor NMDA receptor Ligand-gated ion channel receptors Receptors as enzymes Growth factor receptors Receptors coupled by enzymes Cytokine receptors Cytosolic receptors Steroid receptors as transcript factors Nuclear receptors: thyroid receptor as a transcript factor 4- Drug receptors 4.3 Interactions of drug and receptor D+R DR E Occupation theory: Drug binds to its receptor, then produce physiological effects 4- Drug receptors Binding properties Binding assay(radioactive tests) KD=[D][R] / [DR] Bioassay(biological effect tests) E/Emax=[DR] / [RT]=[D] / {KD+[D]} 4- Drug receptors (1) Affinity(亲和力) ability of drug to bind to the receptor Ligand binding tests:KD;KB In vitro effect test:EC50, pD2(negative log molar concentration of the agonist which produces 50% of the maximal effect) 4- Drug receptors (2) Intrinsic activity(内在活性) Ability of drug to produce effects after binding to the receptor E/Emax=α·[DR] / [RT] Intrinsic activity Affinity Concentration-effect curve:different affinity same intrinsic activity Intrinsic activity Affinity Concentration-effect curve:same affinity different intrinsic activity 4- Drug receptors 4.4 Agonists and antagonists Drugs that act on receptors can be classified into three types based on their affinity, intrinsic activity and produced physiological effect : Full agonist (激动药) Partial agonist (部分激动药) Antagonist (拮抗药) 4- Drug receptors Classification of drugs that acting on receptors Affinity Intrinsic activity Agonist Yes Antagonist Yes Partial agonist Yes Yes(100%) None( 0%) Effects Yes None, blocking agonist Weak(0~100%) Weak , blocking agonist Different patterns of receptor-acting drugs Box 4 Recently,there are new classes of drugs that act on the receptors: inverse agonist (反向激动剂) or negative antagonist (负拮抗剂) 具有拮抗剂特点,本身又产生与激动剂相反的效应。 co-agonist (协同激动剂) 与其它激动剂共同发挥效应。 4- Drug receptors 4.5 Competitive and non-competitive antagonism Competitive antagonists: that compete with agonist for the same binding site on the receptor. Response curve for the agonist are shift to the right without depression of maximal response. 竞争性拮抗药与激动药并用时,能与激动药相互竞争与受体的结合, 降低激动药与受体的亲和力,而不降低内在活性(量效曲线平行右移, 最大效能不变) 4- Drug receptors Non-competitive antagonists: that cause (or not cause) a shift of the response curve to the right with depression of maximal response. 非竞争性拮抗药与激动药并用时,可使亲和力及内在活性均降低,一 般可影响受体功能或与受体不可逆性结合。 Because of Irreversible or pseudo-irreversible binding Allosteric effects Antagonist Antagonist none lower none higher lower higher agonist agonist A:Effect of a competitive antagonist on agonist concentration- response curve B: Effect of a non-competitive antagonist on agonist concentration-response curve 竞争 不可逆/假 不可逆 变构 Possible mechanisms of antagonisms Possible mechanisms of antagonisms 4- Drug receptors Competitive antagonists: Affinity is determined by agonist-antagonist interaction: [A'] / [A]-1=[I] / KI log {[A'] / [A]-1}=log [I]-logKI if [A' ] / [A]=2, then log [I]=log KI=pA2 If [A’ ] = 2[A] Then Log ( [A’]/[A]-1) = 0 Log ( [A’ ]/[A]-1) pA2 0 -log molar concentration of antagonist or -log [I] Schild plot for calculating the affinity of an antagonist 4- Drug receptors pA2 is the negative logarithm of the molar antagonist concentration, in the presence of which twice the original agonist concentration is needed for the original effect. pA2 is equal to the negative logarithm of the given concentration of the antagonist if log([A’/A]-1) equals zero. 4- Drug receptors pA2可定义为:当一定浓度竞争性拮抗药存在时, 激动药浓度需要提高一倍才能达到原来的效应, 此时的竞争性拮抗药浓度的负对数值即为pA2。 pA2的含义:在实验系统中加入拮抗药后,若2倍 浓度的激动药所产生的效应恰好等于未加入拮抗 药时激动药引起的效应,则所加入拮抗药的摩尔 浓度的负对数称为pA2。 4- Drug receptors 4.6 Regulation of receptors (1) Desensitization (脱敏) Receptor phosphorylation Internalization or Endocytosis Reversible 同种脱敏 异种脱敏 Receptor phosphorylation Receptor internalization 4- Drug receptors (2) Changes of receptor numbers Down-regulation (向下调节,下调) Up-regulation(向上调节,上调)